Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
Why Chain of Thought Fails in Clinical Text Understanding
arXiv:2509.21933v2 Announce Type: replace-cross Abstract: Large language models (LLMs) are increasingly being applied to clinical care, a domain where both accuracy and transparent reasoning are critical for safe and trustworthy deployment. Chain-of-thought (CoT) prompting, which elicits step-by-step reasoning, has demonstrated improvements in performance and interpretability across a wide range of tasks. However, its effectiveness in clinical contexts remains largely unexplored, particularly i
-
cs.AI, q-bio.NC updates on arXiv.org
-
Life-Code: Central Dogma Modeling with Multi-Omics Sequence Unification
arXiv:2502.07299v3 Announce Type: replace-cross Abstract: The interactions between DNA, RNA, and proteins are fundamental to biological processes, as illustrated by the central dogma of molecular biology. Although modern biological pre-trained models have achieved great success in analyzing these macromolecules individually, their interconnected nature remains underexplored. This paper follows the guidance of the central dogma to redesign both the data and model pipeline and offers a comprehens
Life-Code: Central Dogma Modeling with Multi-Omics Sequence Unification
-
cs.AI, q-bio.NC updates on arXiv.org
-
BLM$_1$: A Boundless Large Model for Cross-Space, Cross-Task, and Cross-Embodiment Learning
arXiv:2510.24161v1 Announce Type: new Abstract: Multimodal large language models (MLLMs) have advanced vision-language reasoning and are increasingly deployed in embodied agents. However, significant limitations remain: MLLMs generalize poorly across digital-physical spaces and embodiments; vision-language-action models (VLAs) produce low-level actions yet lack robust high-level embodied reasoning; and most embodied large language models (ELLMs) are constrained to digital-space with poor genera
BLM$_1$: A Boundless Large Model for Cross-Space, Cross-Task, and Cross-Embodiment Learning
-
cs.AI, q-bio.NC updates on arXiv.org
-
Generative AI in Depth: A Survey of Recent Advances, Model Variants, and Real-World Applications
arXiv:2510.21887v1 Announce Type: cross Abstract: In recent years, deep learning based generative models, particularly Generative Adversarial Networks (GANs), Variational Autoencoders (VAEs), and Diffusion Models (DMs), have been instrumental in in generating diverse, high-quality content across various domains, such as image and video synthesis. This capability has led to widespread adoption of these models and has captured strong public interest. As they continue to advance at a rapid pace, t
Generative AI in Depth: A Survey of Recent Advances, Model Variants, and Real-World Applications
-
Nature - Issue - nature.com science feeds
-
Aspirin prevents metastasis by limiting platelet TXA<sub>2</sub> suppression of T cell immunity
Nature, Published online: 05 March 2025; doi:10.1038/s41586-025-08626-7Inhibition of cyclooxygenase 1 releases T cells from immunosuppression by platelet-derived thromboxane A2, thereby enhancing the immune response against metastasis.
Aspirin prevents metastasis by limiting platelet TXA<sub>2</sub> suppression of T cell immunity
Nature, Published online: 05 March 2025; doi:10.1038/s41586-025-08626-7
Inhibition of cyclooxygenase 1 releases T cells from immunosuppression by platelet-derived thromboxane A2, thereby enhancing the immune response against metastasis.-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Metastatic brain tumors: from development to cutting-edge treatment
MedComm (2020). 2024 Dec 20;6(1):e70020. doi: 10.1002/mco2.70020. eCollection 2025 Jan.ABSTRACTMetastatic brain tumors, also called brain metastasis (BM), represent a challenging complication of advanced tumors. Tumors that commonly metastasize to the brain include lung cancer and breast cancer. In recent years, the prognosis for BM patients has improved, and significant advancements have been made in both clinical and preclinical research. This review focuses on BM originating from lung cancer
Metastatic brain tumors: from development to cutting-edge treatment
MedComm (2020). 2024 Dec 20;6(1):e70020. doi: 10.1002/mco2.70020. eCollection 2025 Jan.
ABSTRACT
Metastatic brain tumors, also called brain metastasis (BM), represent a challenging complication of advanced tumors. Tumors that commonly metastasize to the brain include lung cancer and breast cancer. In recent years, the prognosis for BM patients has improved, and significant advancements have been made in both clinical and preclinical research. This review focuses on BM originating from lung cancer and breast cancer. We briefly overview the history and epidemiology of BM, as well as the current diagnostic and treatment paradigms. Additionally, we summarize multiomics evidence on the mechanisms of tumor occurrence and development in the era of artificial intelligence and discuss the role of the tumor microenvironment. Preclinically, we introduce the establishment of BM models, detailed molecular mechanisms, and cutting-edge treatment methods. BM is primarily treated with a comprehensive approach, including local treatments such as surgery and radiotherapy. For lung cancer, targeted therapy and immunotherapy have shown efficacy, while in breast cancer, monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates are effective in BM. Multiomics approaches assist in clinical diagnosis and treatment, revealing the complex mechanisms of BM. Moreover, preclinical agents often need to cross the blood-brain barrier to achieve high intracranial concentrations, including small-molecule inhibitors, nanoparticles, and peptide drugs. Addressing BM is imperative.
PMID:39712454 | PMC:PMC11661909 | DOI:10.1002/mco2.70020
-
Omics In Lung
-
Metastatic brain tumors: from development to cutting-edge treatment
MedComm (2020). 2024 Dec 20;6(1):e70020. doi: 10.1002/mco2.70020. eCollection 2025 Jan.ABSTRACTMetastatic brain tumors, also called brain metastasis (BM), represent a challenging complication of advanced tumors. Tumors that commonly metastasize to the brain include lung cancer and breast cancer. In recent years, the prognosis for BM patients has improved, and significant advancements have been made in both clinical and preclinical research. This review focuses on BM originating from lung cancer
Metastatic brain tumors: from development to cutting-edge treatment
MedComm (2020). 2024 Dec 20;6(1):e70020. doi: 10.1002/mco2.70020. eCollection 2025 Jan.
ABSTRACT
Metastatic brain tumors, also called brain metastasis (BM), represent a challenging complication of advanced tumors. Tumors that commonly metastasize to the brain include lung cancer and breast cancer. In recent years, the prognosis for BM patients has improved, and significant advancements have been made in both clinical and preclinical research. This review focuses on BM originating from lung cancer and breast cancer. We briefly overview the history and epidemiology of BM, as well as the current diagnostic and treatment paradigms. Additionally, we summarize multiomics evidence on the mechanisms of tumor occurrence and development in the era of artificial intelligence and discuss the role of the tumor microenvironment. Preclinically, we introduce the establishment of BM models, detailed molecular mechanisms, and cutting-edge treatment methods. BM is primarily treated with a comprehensive approach, including local treatments such as surgery and radiotherapy. For lung cancer, targeted therapy and immunotherapy have shown efficacy, while in breast cancer, monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates are effective in BM. Multiomics approaches assist in clinical diagnosis and treatment, revealing the complex mechanisms of BM. Moreover, preclinical agents often need to cross the blood-brain barrier to achieve high intracranial concentrations, including small-molecule inhibitors, nanoparticles, and peptide drugs. Addressing BM is imperative.
PMID:39712454 | PMC:PMC11661909 | DOI:10.1002/mco2.70020